Crohn’s disease: ethnic variation in CARD15 genotypes

Por Marsh, S, McLeod, H L
Publicado em 2003

Cancer pharmacogenetics

Por Marsh, S, McLeod, H L
Publicado em 2004

Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population

Por McMURROUGH, J., McLEOD, H. L.
Publicado em 1996

Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity.

Por McLeod, H. L., Keith, W. N.
Publicado em 1996

Tumour markers of prognosis in colorectal cancer

Por McLeod, H L, Murray, G I
Publicado em 1999

Laser capture microscopy

Por Curran, S, McKay, J A, McLeod, H L, Murray, G I
Publicado em 2000

Amplification of fluorescent in situ hybridisation signals in formalin fixed paraffin wax embedded sections of colon tumour using biotinylated tyramide.

Por McKay, J A, Murray, G I, Keith, W N, McLeod, H L
Publicado em 1997

Application of laser capture microdissection and proteomics in colon cancer

Por Lawrie, L C, Curran, S, McLeod, H L, Fothergill, J E, Murray, G I
Publicado em 2001

Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.

Por Wei, X, McLeod, H L, McMurrough, J, Gonzalez, F J, Fernandez-Salguero, P
Publicado em 1996

CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia

Por Tayeb, M T, Clark, C, Haites, N E, Sharp, L, Murray, G I, McLeod, H L
Publicado em 2003

Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans.

Por Evans, W E, Relling, M V, Rahman, A, McLeod, H L, Scott, E P, Lin, J S
Publicado em 1993

Unfavourable expression of pharmacologic markers in mucinous colorectal cancer

Por Glasgow, S C, Yu, J, Carvalho, L P, Shannon, W D, Fleshman, J W, McLeod, H L
Publicado em 2005

RNA profiling of cyclooxygenases 1 and 2 in colorectal cancer

Por Church, R D, Yu, J, Fleshman, J W, Shannon, W D, Govindan, R, McLeod, H L
Publicado em 2004

Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034

Por Bissett, D, McLeod, H L, Sheedy, B, Collier, M, Pithavala, Y, Paradiso, L, Pitsiladis, M, Cassidy, J
Publicado em 2001

Comparative genomic hybridization and chromosomal instability in solid tumours

Por Rooney, P H, Murray, G I, Stevenson, D A J, Haites, N E, Cassidy, J, McLeod, H L
Publicado em 1999

Mutations at codon 974 of the DPYD gene are a rare event.

Por Ridge, S. A., Brown, O., McMurrough, J., Fernandez-Salguero, P., Evans, W. E., Gonzalez, F. J., McLeod, H. L.
Publicado em 1997

In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022.

Por McLeod, H. L., Brunton, V. G., Eckardt, N., Lear, M. J., Robins, D. J., Workman, P., Graham, M. A.
Publicado em 1996

Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing

Por Caudle, K E, Thorn, C F, Klein, T E, Swen, J J, McLeod, H L, Diasio, R B, Schwab, M
Publicado em 2013

Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours.

Por McLeod, H. L., Sludden, J., Murray, G. I., Keenan, R. A., Davidson, A. I., Park, K., Koruth, M., Cassidy, J.
Publicado em 1998

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Rasburicase Therapy in the Context of G6PD Deficiency Genotype

Por Relling, M V, McDonagh, E M, Chang, T, Caudle, K E, McLeod, H L, Haidar, C E, Klein, T, Luzzatto, L
Publicado em 2014